Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. (HRMY): 17 pipeline candidates · 3 upcoming catalysts · ~15 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
15.3 months
D/E 0.40 · 2% dilution
Lead: Phase 3
17 candidates
3 upcoming, next in ~1048d
0 buys · 2 sells (180d)
A transparent, data-derived signal for Harmony Biosciences Holdings, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.0B
Cash
$589.7M
Quarterly Burn
$133.6M
Runway
15.3 mo
Revenue
$215.4M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (17 candidates)
| Drug | Phase |
|---|---|
| BP1.15205 | Phase 1 |
| CBS104 | Preclinical |
| CBS105 | Preclinical |
| Clemizole HCl | Phase 3 |
| EPX-100 | Phase 3 |
| EPX-200 | Preclinical |
| HBS-102 | Preclinical |
| pitolisant (Idiopathic Hypersomnia) | Phase 3 |
| pitolisant GR | — |
| pitolisant HD | Phase 3 |
Showing 10 of 17 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
309
Total value held
$1.49B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 7,070,035 | $198.0M |
| vanguard capital management llc | 4,204,630 | $117.8M |
| fmr llc | 3,157,639 | $88.4M |
| vanguard portfolio management llc | 2,714,353 | $76.0M |
| american century companies inc | 2,105,179 | $59.0M |
| dimensional fund advisors lp | 2,076,510 | $58.2M |
| state street corp | 1,784,362 | $50.0M |
| armistice capital, llc | 1,624,000 | $45.5M |
| arrowstreet capital, limited partnership | 1,382,113 | $38.7M |
| geode capital management, llc | 1,322,720 | $37.1M |
Showing top 10 of 309 institutional holders of Harmony Biosciences Holdings, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Harmony Biosciences Holdings, Inc.'s pipeline?
Harmony Biosciences Holdings, Inc. (HRMY) has 17 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Harmony Biosciences Holdings, Inc.'s lead drug candidate?
Harmony Biosciences Holdings, Inc.'s most advanced tracked candidate is BP1.15205 (Phase 1) for Narcolepsy and other potential indications.
What is Harmony Biosciences Holdings, Inc.'s next catalyst?
Harmony Biosciences Holdings, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydr" — expected May 1, 2029.
What is Harmony Biosciences Holdings, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Harmony Biosciences Holdings, Inc. has approximately 15.3 months of cash runway.
What is Harmony Biosciences Holdings, Inc.'s market capitalization?
Harmony Biosciences Holdings, Inc.'s market capitalization is approximately $2.0B.
Get the full picture on Harmony Biosciences Holdings, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.